Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24634129 | 1.00 | EP300 (0.36) | EP300HIF1ACREBBPOPRK1 | |
| SCHEMBL19853719 | 0.87 | OPRK1 (0.33) | OPRK1 | |
| SCHEMBL23153058 | 0.87 | OPRK1 (0.33) | OPRK1 | |
| SCHEMBL19854898 | 0.87 | EP300 (0.35) | EP300HIF1ACREBBP | |
| SCHEMBL19853669 | 0.86 | OPRK1 (0.33) | OPRK1 | |
| SCHEMBL19854868 | 0.86 | OPRK1 (0.33) | OPRK1 | |
| SCHEMBL19854895 | 0.86 | EP300 (0.33) | EP300HIF1ACREBBP | |
| SCHEMBL19853680 | 0.85 | LMNA (0.36) | EP300HIF1ACREBBP | |
| SCHEMBL19853730 | 0.85 | EP300 (0.34) | EP300HIF1ACREBBP | |
| SCHEMBL19854897 | 0.83 | EP300 (0.33) | EP300HIF1ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| WO-2018026763-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | EP300 1590/4885HIF1A 4440/4885CREBBP 1085/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | EP300 1590/4885HIF1A 4440/4885CREBBP 1085/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | EP300 1161/4885HIF1A 4463/4885CREBBP 1030/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | EP300 1590/4885HIF1A 4440/4885CREBBP 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.